7Baggers

We provide you with 20 years of free, institutional-grade data for IDYA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IDYA. Explore the full financial landscape of IDYA stock.

Reported DateCIKTickerType
2025-08-051676725IDYA10-QUrl
2025-05-061676725IDYA10-QUrl
2025-02-181676725IDYA10-KUrl
2024-11-041676725IDYA10-QUrl
2024-08-061676725IDYA10-QUrl
2024-05-071676725IDYA10-QUrl
2024-02-201676725IDYA10-KUrl
2023-11-071676725IDYA10-QUrl
2023-08-101676725IDYA10-QUrl
2023-05-091676725IDYA10-QUrl
2023-03-071676725IDYA10-KUrl
2022-11-081676725IDYA10-QUrl
2022-08-151676725IDYA10-QUrl
2022-05-101676725IDYA10-QUrl
2022-03-181676725IDYA10-KUrl
2021-11-151676725IDYA10-QUrl
2021-08-101676725IDYA10-QUrl
2021-05-101676725IDYA10-QUrl
2021-03-231676725IDYA10-KUrl
2020-11-121676725IDYA10-QUrl
2020-08-121676725IDYA10-QUrl
2020-05-121676725IDYA10-QUrl
2020-03-241676725IDYA10-KUrl
2019-11-131676725IDYA10-QUrl
2019-08-121676725IDYA10-QUrl
2019-04-261676725IDYAS-1Url

IDEAYA Biosciences, Inc
(NASDAQ:IDYA) 

IDYA stock logo

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is...

Founded: 2015
IPO Price: $10 (May 23, 2019)
Full Time Employees: 58
CEO: Yujiro S. Hata  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about IDYA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.